Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study.

ABSTRACT:

Background

Durvalumab supplementation may have some potential in improving the efficacy in patients with non-small-cell lung cancer (NSCLC), and this meta-analysis aims to explore the impact of durvalumab supplementation on efficacy for NSCLC.

Methods

PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched, and we included randomized controlled trials (RCTs) assessing the effect of durvalumab supplementation on efficacy in patients with NSCLC. Overall survival and progression-free survival were included for this meta-analysis.

Results

Four RCTs were finally included in the meta-analysis. Overall, compared with control group for NSCLC, durvalumab supplementation showed significantly improved survival rate (odd ratio [OR] = 1.6

SUBMITTER: Wang C 

PROVIDER: S-EPMC11223428 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature